HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?].

Abstract
Looking at the most frequent urological tumors kidney cancer has the worst prognosis. Primary therapy consists of operative tumor removal in most cases. A tumor cutoff between 4 and 5 cm represents the turn towards a significant risk for postoperative tumor relapse. In those patients neoadjuvant or adjuvant therapy would be indicated. However, no phase III trials on neoadjuvant therapy of kidney cancer have been published in the literature. In contrast, five phase III trials on adjuvant therapy of kidney cancer have been published. In four trials interferon-alpha and/or interleukin-2 were applied. None of these trials had a positive outcome. Moreover, adjuvant cytokine therapy was associated with significant side effects in 30% of patients. In the fifth trial an autologous tumor cell vaccine (Reniale) demonstrated an improvement of progression-free survival and overall survival. Also, there were less than 1% side effects. Results from active trials investigating a combination of interleukin-2, interferon-alpha and 5-FU, or a heat shock protein vaccine or an antibody are awaited soon. New trials are testing tyrosine kidney inhibitors such as sunitinib and sorafenib.
AuthorsC Doehn, A S Merseburger, D Jocham, M A Kuczyk
JournalDer Urologe. Ausg. A (Urologe A) Vol. 46 Issue 10 Pg. 1371-2, 1374, 1376-8 (Oct 2007) ISSN: 0340-2592 [Print] Germany
Vernacular TitleGibt es eine Indikation zur neoadjuvanten oder adjuvanten Systemtherapie beim Nierenzellkarzinom?
PMID17805507 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Cancer Vaccines
  • Interferon-alpha
  • Interleukin-2
  • Fluorouracil
Topics
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Cancer Vaccines (administration & dosage, adverse effects)
  • Carcinoma, Renal Cell (drug therapy, mortality, pathology, surgery)
  • Chemotherapy, Adjuvant
  • Clinical Trials, Phase III as Topic
  • Combined Modality Therapy
  • Disease-Free Survival
  • Fluorouracil (administration & dosage, adverse effects)
  • Humans
  • Interferon-alpha (administration & dosage, adverse effects)
  • Interleukin-2 (administration & dosage, adverse effects)
  • Kidney Neoplasms (drug therapy, mortality, pathology, surgery)
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Nephrectomy
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: